Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding
Authors:
Top Cited Papers
Open Access
- 20 December 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 19 (12) , e1011868
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB lineages have achieved dominance worldwide and keep on evolving. Convergent evolution of XBB lineages on the receptor-binding domain (RBD) L455F and F456L is observed, resulting in variants with substantial growth advantages, such as EG.5, FL.1.5.1, XBB.1.5.70, and HK.3. Here, we show that neutralizing antibody (NAb) evasion drives the convergent evolution of F456L, while the epistatic shift caused by F456L enables the subsequent convergence of L455F through ACE2 binding enhancement and further immune evasion. L455F and F456L evade RBD-targeting Class 1 public NAbs, reducing the neutralization efficacy of XBB breakthrough infection (BTI) and reinfection convalescent plasma. Importantly, L455F single substitution significantly dampens receptor binding; however, the combination of L455F and F456L forms an adjacent residue flipping, which leads to enhanced NAbs resistance and ACE2 binding affinity. The perturbed receptor-binding mode leads to the exceptional ACE2 binding and NAb evasion, as revealed by structural analyses. Our results indicate the evolution flexibility contributed by epistasis cannot be underestimated, and the evolution potential of SARS-CoV-2 RBD remains high.Keywords
All Related Versions
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2023YFC3041500)
- Ministry of Science and Technology of the People's Republic of China (2023YFC3043200)
- Changping Laboratory (2021A0201)
- Changping Laboratory (2021D0102)
- Excellent Young Scientists Fund (32222030)
This publication has 45 references indexed in Scilit:
- Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccineCell Research, 2021
- Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2Nature Communications, 2021
- Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccinesCell Research, 2021
- Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicryNature Communications, 2021
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategiesNature, 2020
- An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding DomainCell Reports, 2020
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibodyNature, 2020
- GISAID: Global initiative on sharing all influenza data – from vision to realityEurosurveillance, 2017
- Epistasis in protein evolutionProtein Science, 2016
- Stability-mediated epistasis constrains the evolution of an influenza proteineLife, 2013